Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266417 · ClinicalTrials.gov registry record · Phase 2
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
A Phase 2 study of Parkinson Disease, sponsored by Gateway Institute for Brain Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT05266417: Recruiting Phase 2 study of Parkinson Disease, sponsored by Gateway Institute for Brain Research.
NCT05266417 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Gateway Institute for Brain Research. The registered enrollment target is 56 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05266417, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Gateway Institute for Brain Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
Primary Outcome
F, A and S (FAS) words test
Conditions Studied
Interventions
- DRUG INS-GSH
- DRUG Matched Placebos
Study Locations (2)
Florida
- Institute for Neuroimmune Medicine - Davie
- Las Mercedes Medical Research - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
What NCT05266417 shows while recruiting
NCT05266417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which INS-GSH is the first listed.
NCT05266417 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05266417 about?
NCT05266417 is a clinical study titled "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease". This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
What is the current status of trial NCT05266417?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-02-07. Estimated completion is 2027-01-30.
What conditions does trial NCT05266417 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05266417?
The interventions under investigation include: INS-GSH (DRUG), Matched Placebos (DRUG).
Who is sponsoring clinical trial NCT05266417?
This trial is sponsored by Gateway Institute for Brain Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05266417 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05266417's enrollment target sits among peer trials
56 148th of 297 higher than 150 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
-
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI